Details for Patent: 7,456,207
✉ Email this page to a colleague
Which drugs does patent 7,456,207 protect, and when does it expire?
Patent 7,456,207 protects VANDAZOLE and is included in one NDA.
This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 7,456,207
| Title: | Vaginal pharmaceutical compositions and methods for preparing them |
| Abstract: | Vaginal pharmaceutical compositions are described. These compositions contain (i) an active pharmaceutical ingredient selected from the group consisting of antimicrobial imidazoles and mixtures thereof, and (ii) a polysaccharide, wherein the pH of the composition is greater than 4.25 and less than about 8. In particularly preferred compositions, the active pharmaceutical ingredient includes metronidazole and the polysaccharide includes hypromellose. These compositions can be applied to vaginal tissue for treatment of various diseases, such as bacterial vaginosis, or for prophylaxis. |
| Inventor(s): | Bentley; Christine Lynn (Caledonia, MI), Feldtmose; Karen (Pennsburg, PA) |
| Assignee: | Teva Pharmaceuticals USA, Inc. (PA) |
| Application Number: | 10/946,133 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Device; |
Drugs Protected by US Patent 7,456,207
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms | VANDAZOLE | metronidazole | GEL;VAGINAL | 021806-001 | May 20, 2005 | BX | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
